Field safety study of VANGUARD®crLyme: A vaccine for the prevention of Lyme disease in dogs.

Borrelia Borreliella C6 Chimeritope Ixodes Lyme disease Ticks Vaccine

Journal

Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769

Informations de publication

Date de publication:
11 Dec 2020
Historique:
received: 28 08 2020
revised: 17 10 2020
accepted: 19 10 2020
entrez: 18 12 2020
pubmed: 19 12 2020
medline: 19 12 2020
Statut: epublish

Résumé

Here we report the results of a large-scale pre-license safety study in which two serials of VANGUARD®crLyme, a vaccine for canine Lyme disease, were tested in its target population (dogs) under the conditions of its intended use. Six-hundred and twenty dogs, from three distinct geographic regions of the United States were enrolled in this study with each receiving two doses of vaccine by subcutaneous injection 3 to 4 weeks apart. Approximately one-third of the dogs were of minimum age (≤8 weeks of age) to meet regulatory requirements. Safety was evaluated by observation of local and systemic reactions for at least 10 days after each vaccination. Abnormal health events (AHEs) occurred at low frequencies and no serious AHEs were observed. The results demonstrated that VANGUARD®crLyme is safe for use in healthy dogs 8 weeks of age or older.

Identifiants

pubmed: 33336186
doi: 10.1016/j.jvacx.2020.100080
pii: S2590-1362(20)30027-9
pmc: PMC7733143
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100080

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Vaccine. 2007 Jan 5;25(3):466-80
pubmed: 16996663
Antonie Van Leeuwenhoek. 2014 Jun;105(6):1049-72
pubmed: 24744012
BMC Vet Res. 2018 Oct 16;14(1):312
pubmed: 30326885
Science. 1982 Jun 18;216(4552):1317-9
pubmed: 7043737
Vaccine. 2020 Feb 18;38(8):1915-1924
pubmed: 31959423
Vaccine. 2007 Apr 30;25(17):3419-27
pubmed: 17239505
Infect Dis Clin North Am. 2015 Jun;29(2):187-210
pubmed: 25999219
N Engl J Med. 1983 Mar 31;308(13):740-2
pubmed: 6828119
Clin Vaccine Immunol. 2006 Oct;13(10):1162-5
pubmed: 17028218
J Clin Microbiol. 2000 Jan;38(1):382-8
pubmed: 10618120

Auteurs

Richard T Marconi (RT)

Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, VA 23298-0678, United States.

Nicole Honsberger (N)

Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.

M Teresa Winkler (M)

Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.

Nikki Sobell (N)

Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.

Vickie L King (VL)

Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.

Sharon Wappel (S)

Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.

Jacquelien Hoevers (J)

Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.

Zach Xu (Z)

Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.

Jason Millership (J)

Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.

Classifications MeSH